Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Epidemiology and economics of chemotherapy combinations in the treatment of advanced breast cancer
Autore:
Martin, JP; Dieras, V; Berdeaux, G;
Indirizzi:
Clin St Jean, F-69008 Lyon, France Clin St Jean Lyon France F-69008Clin St Jean, F-69008 Lyon, France Inst Curie, F-75248 Paris 05, France Inst Curie Paris France 05Inst Curie, F-75248 Paris 05, France Labs Pierre Fabre Medicament, F-92654 Boulogne, France Labs Pierre Fabre Medicament Boulogne France F-92654 54 Boulogne, France
Titolo Testata:
THERAPIE
fascicolo: 1, volume: 55, anno: 2000,
pagine: 127 - 131
SICI:
0040-5957(200001/02)55:1<127:EAEOCC>2.0.ZU;2-V
Fonte:
ISI
Lingua:
FRE
Soggetto:
2ND-LINE CHEMOTHERAPY; VINORELBINE; PACLITAXEL; DOCETAXEL; BIAS;
Keywords:
chemotherapy; advanced breast cancer; cost; utility; economics; pharmacoepidemiology;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
13
Recensione:
Indirizzi per estratti:
Indirizzo: Berdeaux, G Clin St Jean, 30 Rue Bataille, F-69008 Lyon, France Clin St Jean 30 Rue Bataille Lyon France F-69008 Lyon, France
Citazione:
J.P. Martin et al., "Epidemiology and economics of chemotherapy combinations in the treatment of advanced breast cancer", THERAPIE, 55(1), 2000, pp. 127-131

Abstract

125 oncologists, taken at random from a French professional list, followedup a cohort of 836 patients suffering from advanced breast cancer and treated by chemotherapy. Thk following data were collected prospectively: socio-demographics of patients and practitioners, disease history, characteristics of one chemotherapy cycle (type, utility and cost). A total of 89 chemotherapy combinations were described during the first-line treatment, independently of doses, eight combinations representing 70 per cent of all the prescriptions. No statistically significant differences were found when comparing the utility of the most often used combinations. Chemotherapy was the main cost driver of administration, rising to 90 per cent of the total cost when using taxans, followed by CSF. The cost price of taxan administration was twice to three times that of FEC or vinorelbine associations. These differences were poorly taken into account by the French budget allocation system as based on Diagnosis Related Groups.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/01/20 alle ore 18:53:05